MLN8237, an Aurora A kinase inhibitor, for treatment of myeloid malignancies

Adults with fibrotic myeloid malignancies (acute megakaryoblastic leukemia and primary myelofibrosis) have limited effective therapy options. Most patients will die from these diseases. In our LLS TRP funded research with primary samples and animal models, we discovered that inhibition of Aurora A kinase significantly ameliorates these malignancies. This goal of this project will be to conduct a clinical investigation of MLN8237, a novel inhibitor of Aurora A kinase, in adult patients with relapsed and refractory acute megakaryoblastic leukemia or primary myelofibrosis.